FY2025 EPS Estimates for Immatics Lowered by Chardan Capital

Immatics N.V. (NASDAQ:IMTX) – Stock analysts at Chardan Capital dropped their FY2025 earnings per share estimates for Immatics in a research report issued to clients and investors on Monday, November 24th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($1.76) for the year, down from their prior forecast of ($1.47). Chardan Capital has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

Immatics (NASDAQ:IMTX) last issued its earnings results on Monday, November 17th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.01. Immatics had a negative net margin of 146.13% and a negative return on equity of 24.16%. The company had revenue of $6.10 million for the quarter, compared to analyst estimates of $12.53 million.

Several other brokerages have also recently commented on IMTX. Zacks Research upgraded shares of Immatics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Guggenheim upped their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Mizuho increased their target price on Immatics from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immatics presently has an average rating of “Moderate Buy” and a consensus price target of $19.25.

Immatics Price Performance

Shares of NASDAQ IMTX opened at $10.61 on Thursday. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $11.25. The firm has a market capitalization of $1.29 billion, a P/E ratio of -10.40 and a beta of 1.24. The company’s 50 day simple moving average is $9.52 and its 200 day simple moving average is $7.08.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. acquired a new position in Immatics in the third quarter valued at about $2,556,000. Verition Fund Management LLC bought a new position in shares of Immatics during the 3rd quarter valued at about $385,000. Vestal Point Capital LP grew its position in shares of Immatics by 1.6% in the 3rd quarter. Vestal Point Capital LP now owns 6,350,000 shares of the company’s stock valued at $54,102,000 after purchasing an additional 100,000 shares during the period. Millennium Management LLC grew its position in shares of Immatics by 4,991.1% in the 3rd quarter. Millennium Management LLC now owns 721,866 shares of the company’s stock valued at $6,150,000 after purchasing an additional 707,687 shares during the period. Finally, Baker BROS. Advisors LP increased its stake in Immatics by 18.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after purchasing an additional 1,925,193 shares in the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.